Mitsuyoshi Azuma
Directeur/Membre du Conseil chez Senju Pharmaceutical Co., Ltd.
Provenance du réseau au premier degré de Mitsuyoshi Azuma
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
Senju Pharmaceutical Co., Ltd.
 Senju Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Senju Pharmaceutical Co., Ltd. manufactures and distributes pharmaceuticals. It produces drugs for inflammation, allergy, glaucoma, cataract, and infection. The company was founded on April 9, 1947 and is headquartered in Osaka, Japan.
7
| Private Company | Pharmaceuticals: Major | 7 |
Neuroptika, Inc.
 Neuroptika, Inc. Pharmaceuticals: MajorHealth Technology Neuroptika, Inc. operates as biotechnology company which develops drugs for eye diseases and nerves regeneration. The company was founded by Chiho Fukiage and in November 2018 and is headquartered in Cambridge, MA.
5
| Holding Company | Pharmaceuticals: Major | 5 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Mitsuyoshi Azuma via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| Seoul National University | College/University | Graduate Degree | |
KTB Network Co., Ltd. (Venture Capital)
 KTB Network Co., Ltd. (Venture Capital) Investment ManagersFinance KTB Network Co., Ltd. (Venture Capital) is a venture capital subsidiary of Daol Investment Co., Ltd. founded in 1981. KTB Network Co., Ltd. (Venture Capital) is headquartered in Seongnam, South Korea with offices in Shanghai, Palo Alto and Singapore. | Investment Managers | Private Equity Investor | |
| Konan University | College/University | Graduate Degree | |
| Kyungsung University | College/University | Undergraduate Degree | |
| EYENOVIA, INC. | Pharmaceuticals: Major | Director/Board Member | |
| BRIDGE BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
GenEdit, Inc.
 GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Pharmaceuticals: Major | Director/Board Member | |
SemaThera, Inc.
 SemaThera, Inc. BiotechnologyHealth Technology SemaThera, Inc. engages in research and development in biotechnology. It develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). The company is headquartered in Montreal, Canada. | Biotechnology | Director/Board Member | |
Deepbiome Therapeutics, Inc.
 Deepbiome Therapeutics, Inc. BiotechnologyHealth Technology Deepbiome Therapeutics, Inc. engages in biotechnology operations to develop a new drug discovery platform. The company is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member |
Statistiques
Internationale
| Corée du Sud | 5 |
| Etats-Unis | 4 |
| Japon | 2 |
| Canada | 2 |
Sectorielle
| Health Technology | 6 |
| Consumer Services | 4 |
| Finance | 2 |
Opérationnelle
| Director/Board Member | 12 |
| Corporate Officer/Principal | 5 |
| President | 3 |
| Chief Executive Officer | 2 |
| Chief Operating Officer | 2 |
Relations les plus connectées
- Bourse
- Insiders
- Mitsuyoshi Azuma
- Connexions Sociétés
